Pyrazolam
Viewing r1 — May 9, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Pyrazolam is a synthetic depressant of the benzodiazepine class. It is structurally derived from triazolam, distinguished by an unusually selective anxiety-reducing profile. It enhances GABA, the brain's main calming neurotransmitter, producing anxiety suppression with less sedation than most benzodiazepines.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
benzodiazepines, zolpidem, zaleplon +2 morebenzodiazepines, zolpidem, zaleplon, barbiturates, alcohol show less
Synthesized at Hoffmann-La Roche in the early 1970s, pyrazolam was never brought to market as a medicine.[2] It resurfaced in 2012 as one of the first designer benzodiazepines sold online, marking the start of an entirely new class of unregulated compounds.[3] It remains federally unscheduled in the United States but is controlled in the United Kingdom, Germany, and several other countries.
Subjective effects include anxiety relief, mild sedation, muscle relaxation, and cognitive slowing.[4] The experience is defined by what it removes — anxiety recedes cleanly, without the euphoria, heavy sedation, or mental fog typical of most benzodiazepines, making the effect highly sensitive to baseline anxiety level.[5] Residual impairment beyond the felt-effects window, a false sense of sobriety, and difficulty stopping redosing are characteristic unwanted effects.
Pyrazolam produces high abuse liability with regular use, and withdrawal can include seizures.[6] The mechanism places a ceiling on overdose risk from pyrazolam alone, but combining it with opioids, alcohol, or other depressants removes that ceiling.[7] No clinical trials exist — what is known comes from a single self-administration case study and structural inference from related compounds.[8]
History[edit]
Discovery
Pyrazolam was synthesized by Leo Sternbach and Armin Walser at Hoffmann-La Roche, documented in US Patent 3,954,728 filed in 1972.[2] Despite showing pharmacological activity, it was never advanced into development and remained a laboratory curiosity for four decades.
Emergence as a designer benzodiazepine
Pyrazolam reappeared around 2012 on online research chemical markets. Researchers described its emergence as marking "the beginning of designer benzodiazepines being sold as recreational drugs".[3] It was one of three founding compounds in the first wave of designer benzodiazepines, alongside diclazepam and flubromazepam.[9]
Regulatory response
Pyrazolam was flagged to the European drug early-warning system in 2013.[10] The United Kingdom classified it as Class C in June 2017,[5] and Germany brought it under its new psychoactive substances law in 2019. It remains federally unscheduled in the United States as of 2026.
The name pyrazolam follows benzodiazepine naming convention: the -azolam suffix marks it as a triazolobenzodiazepine, shared with triazolam and alprazolam, while the pyr- prefix references the pyridine ring at position 6. Online communities valued pyrazolam as the functional benzodiazepine — narrow anxiolysis without recreational sedation or euphoria, a quality that set it apart from the compounds that followed.[5]
Chemistry[edit]
Structural class
Pyrazolam is a triazolobenzodiazepine — a structural family that includes triazolam and alprazolam. The defining feature is a triazole ring fused onto a benzodiazepine scaffold, giving these compounds greater structural rigidity than classic benzodiazepines like diazepam.
Molecular structure
| Molecular formula | C₁₆H₁₂BrN₅ |
| Molecular weight | 354.20 g/mol |
Pyrazolam differs from triazolam at two positions: a bromine atom replaces a chlorine, and a pyridine ring replaces a chlorophenyl group.[11] These changes shift which receptor subtypes it targets most strongly and alter how the body processes it.
Pharmacology[edit]
Mechanism of action
Pyrazolam enhances GABA, the brain's primary calming neurotransmitter, by binding to the benzodiazepine site on GABA-A receptors and amplifying their response.[1] It does not directly activate the receptors — it turns up the volume on signals that are already present.
What distinguishes pyrazolam from most benzodiazepines is its apparent preference for receptor subtypes associated with anxiety relief over those that drive sedation and memory loss.[12][13] Direct binding data confirming this selectivity have not been published — the evidence is indirect, drawn from related compounds and consistent user reports.[5]
Pharmacokinetics
The only published human data come from a single self-administration study: one researcher who ingested 1 mg orally.[8] The half-life was approximately 17 hours — far longer than the 5–8 hour window of felt effects and the 6-hour figure marketed by vendors.[5] How pyrazolam breaks down in the body remains unresolved: three separate studies have produced contradictory results.[8][14][15]
Neuroscience[edit]
Where it acts
Pyrazolam's effects are shaped by which GABA receptor subtypes it targets most strongly. Receptors in the amygdala — the brain's fear center — dampen anxiety responses without broadly suppressing the cortex.[12] Receptors in the brainstem modulate arousal and muscle tone. At higher doses, the selectivity narrows and sedation, cognitive slowing, and memory effects emerge.
Why it matters
Pyrazolam functions as an unintentional test of a long-pursued idea: that anxiety suppression can be pharmacologically separated from sedation and memory loss.[12] No deliberately designed drug of this kind has reached clinical approval. Yet user reports consistently describe pronounced anxiety relief with limited sedation — indirect human evidence that the separation is achievable.[5]
The key missing experiment is a direct measurement of pyrazolam's binding affinity at each receptor subtype — the entire selectivity claim rests on inference. Whether this selectivity slows tolerance development compared to non-selective benzodiazepines is unknown but clinically significant.[6] The contradiction in metabolic findings across three studies[8][14][15] also remains unresolved.
Subjective Effects[edit]
Pyrazolam's character is defined by what it removes. Anxiety recedes, social stress softens, and the mind quiets — but colors don't shift, time doesn't distort, and euphoria is largely absent. At higher doses, sedation and cognitive fog arrive, but the baseline experience is narrow and functional.
Among designer benzodiazepines, pyrazolam most resembles diclazepam — both are considered functional rather than recreational, with minimal sedation at anxiolytic doses. The contrast with clonazolam is sharp: clonazolam produces heavy sedation, amnesia, and euphoria at sub-milligram doses, while pyrazolam at comparable doses leaves cognition and coordination largely intact.[9]
Effect Grid
At 0.75–1.5 mg, pyrazolam produces clear, sustained anxiety suppression — the primary therapeutic-equivalent range. Anxiolysis is the dominant effect: worry, anticipatory anxiety, and social apprehension are substantially reduced. Mild thought deceleration and analysis suppression emerge, particularly at the upper end of the range.
Sedation becomes noticeable but remains mild. Muscle relaxation is present and perceptible. Motor control is slightly reduced at 1.5 mg but largely preserved at 0.75 mg. Some users report mild physical fatigue. Emotional suppression becomes apparent — emotional reactivity is dampened.
Cognitive function remains substantially preserved at the lower end; mild cognitive impairment emerges at the upper end. Amnesia risk is low but nonzero. The 17-hour half-life means residual drug persists long after subjective effects fade — avoid redosing within 8 hours.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Dizziness · Body high · Nystagmus (eye wobbles) · Breathing alteration · Nausea suppression · Nausea
Nausea suppression · Nausea
Information processing suppression · Cognitive fatigue · Analysis suppression · Thought deceleration · Motivation suppression · Cognitive euphoria · Memory fragmentation · Language suppression · Thought disorganization · Compulsive redosing urge · Confusion · Amnesia
Thought deceleration · Motivation suppression · Cognitive euphoria · Memory fragmentation · Language suppression · Thought disorganization · Confusion · Amnesia
Timeline
Initial absorption begins. A subtle easing of baseline anxiety may emerge in the final minutes of this phase, though many users report no perceptible change until the come-up.
Anxiolysis intensifies to its full character. Mild muscle relaxation begins. The effect is experienced as a steady quieting of anxious thought rather than a sudden shift.
Maximum anxiety suppression. Sedation and muscle relaxation hold at a stable plateau. At common doses, cognitive function remains largely preserved — the peak is notable for its functional clarity relative to other benzodiazepines.
Anxiolysis and sedation gradually diminish. Effects fade below the threshold of subjective awareness over several hours. Some users do not notice the offset clearly due to the gradual taper.
No positive afterglow in the psychedelic sense. Residual pharmacological activity persists due to the 17-hour elimination half-life — subtle psychomotor impairment is possible without subjective awareness.
⚠ Do not drive or operate machinery for at least 24 hours after the last dose.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- Moderate
- Dose escalation
- High
- Cross-tol.
- benzodiazepines · zolpidem · zaleplon
Toxicity
Acute toxicity
As a GABA enhancer, pyrazolam has a built-in safety ceiling: the mechanism limits how much it can depress the brain, making death from pyrazolam alone unlikely in otherwise healthy individuals. No lethal dose data exist for any species.
The one published fatality involving pyrazolam was a polydrug case — co-detected substances included diclazepam, 3-fluorophenmetrazine, amphetamine, and caffeine.[7] A published poisoning involved co-ingestion with high-concentration alcohol, treated with a reversal agent.[16] Pyrazolam has been identified in intoxication cases through the Swedish STRIDA project[17] and in blood samples from impaired drivers in Norway.[18]
The primary acute risk is polydrug toxicity. Co-administration with opioids, alcohol, barbiturates, GHB, or other depressants eliminates the safety ceiling that protects against benzodiazepine-only overdose. Both the published fatality and the published poisoning case involved polydrug contexts.
Chronic toxicity
No substance-specific chronic toxicity data exist for pyrazolam. Long-term benzodiazepine use as a class is associated with cognitive impairment — particularly affecting memory and reaction time — and increased fall risk in elderly populations.
Psychological risks
Amnesia and blackout: Memory loss is a class effect of benzodiazepines; it becomes probable at strong and heavy doses.[9]
Delusions of sobriety: Users may underestimate their impairment while demonstrating measurable deficits in coordination and judgment.
Disinhibition: Reduced impulse control can produce aggression, impulsivity, or risk-taking, amplified by concurrent alcohol use.
Compulsive redosing: Some users report difficulty stopping once started, though pyrazolam is considered less reinforcing than high-euphoria compounds like clonazolam.[4]
Rebound anxiety: anxiety exceeding baseline levels may follow cessation, driving repeated use and contributing to the dependence cycle.
Drug-facilitated crime: Limited detectability on standard drug panels and amnestic potential at higher doses place pyrazolam in a moderate risk category among designer benzodiazepines.[19]
Tolerance and dependence
Tolerance develops rapidly with continuous use — typically within days to weeks — through downregulation.[6] Full cross-tolerance exists with all benzodiazepines, barbiturates, and alcohol.
Physical dependence follows sustained use, with withdrawal that can include anxiety, insomnia, tremor, sweating, and — in severe cases — seizures.[8] Psychological dependence builds through repeated anxiety suppression, and recovery typically requires medically supervised substitution with a long-acting benzodiazepine followed by gradual taper.[20][21]
Drug interactions
CNS depressant potentiation (dangerous to potentially fatal): Combining pyrazolam with alcohol, opioids, other benzodiazepines, barbiturates, GHB, or gabapentinoids produces additive or synergistic depression of consciousness and breathing.[6] Opioids suppress breathing directly; benzodiazepines reduce the arousal response that would otherwise wake a person up — this combination is responsible for the majority of benzodiazepine-involved overdose deaths. The published fatality involved pyrazolam with Diclazepam and stimulants;[7] the published poisoning involved co-ingestion with alcohol.[16]
Stimulant combinations: Use as a stimulant comedown aid was reported in 16.1% of online forum discussions.[5] While less acutely dangerous than depressant combinations, this pattern can reinforce escalating use of both substances.
Contraindications
Respiratory insufficiency (absolute): Pre-existing breathing conditions such as COPD or sleep apnea increase vulnerability to GABA-mediated respiratory depression.
Concurrent depressant use (absolute): Active use of opioids, barbiturates, alcohol, GHB, or other benzodiazepines — synergistic respiratory depression risk eliminates the safety ceiling.
History of benzodiazepine dependence (relative): Prior use disorder significantly increases relapse risk; cross-tolerance means any prior GABAergic dependence compounds the risk.
Liver impairment (relative): Metabolic fate is uncertain, but any liver processing could be prolonged by liver disease.inferred
Pregnancy (absolute): Benzodiazepines carry risk of birth defects with first-trimester exposure and neonatal withdrawal with late-pregnancy exposure.inferred
Myasthenia gravis (absolute): Benzodiazepine-mediated muscle relaxation and respiratory depression can precipitate crisis.
Harm Reduction[edit]
Forms & Identification
Pyrazolam's active dose begins below 1 mg. Powder form demands a milligram-precision scale — estimation by volume is unreliable and risks overshooting into sedation and amnesia.
Pressed pellets are more convenient but come from unregulated manufacturing with no quality guarantee. Standard benzodiazepine drug panels do not reliably detect pyrazolam, and reagent kits cannot distinguish between benzodiazepine analogs.[9] Laboratory analysis is the only definitive identification method.
Guidelines
- Start with the lowest available dose to assess individual sensitivity before considering any increase
- Weigh powder doses with a milligram-precision scale — never estimate by eye
- Set a firm dose limit before taking the first dose; benzodiazepine-induced impairment erodes the judgment needed to stop redosing
- Allow at least 90 minutes before considering whether to redose — onset can be delayed
- Do not combine with alcohol, opioids, GHB, or any other depressant
- Avoid frequent or consecutive-day use; physical dependence can develop within days to weeks of regular use
- Inform a trusted person of the substance, dose, and timing
- Keep a written record of dose and time — memory suppression may prevent accurate recall
Set & Setting
Pyrazolam's effect is strongly shaped by baseline anxiety. Those without significant anxiety may perceive little change and be tempted to redose — a pattern that risks overshooting into sedation and amnesia. A calm, familiar environment reduces the temptation to chase an effect that may not be perceptible without anxiety to relieve.
The 17-hour half-life means pyrazolam remains pharmacologically active well beyond the 5–8 hour period of felt effects. Planning should account for next-day impairment, particularly for driving, operating machinery, or making important decisions.
Aftercare & integration. Residual effects from pyrazolam's 17-hour half-life may include subtle cognitive slowing, reduced reaction time, and emotional suppression for 24–48 hours after felt effects resolve. Tasks requiring sharp judgment or fast reflexes should be avoided during this period.
Those who take pyrazolam to manage anxiety should consider whether the underlying anxiety has a treatable cause. Benzodiazepine self-medication masks symptoms without addressing their source, and rebound effect anxiety after each use can worsen the original problem over time. Evidence-based treatment through a healthcare provider is safer and more effective.
Recovery & Support
Benzodiazepine dependence requires careful, medically supervised withdrawal. Abrupt cessation after regular use risks seizures, which can be life-threatening. The standard clinical approach is substitution with a long-acting benzodiazepine such as diazepam, followed by gradual taper over weeks to months.[21]
Escalating use, inability to skip days, or withdrawal symptoms between doses are signals to seek medical support. The Benzodiazepine Information Coalition (benzoinfo.com) and SAMHSA's helpline (1-800-662-4357) provide resources and referrals. Recovery is achievable but benefits from professional guidance — the withdrawal process is physiologically complex and should not be self-managed.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: The line between uncomfortable and dangerous crosses when breathing becomes slow or shallow, skin or lips develop a blue tint, the person cannot be roused by voice or physical stimulation, or vomiting occurs while semiconscious.
Immediate steps:
- 1. Call emergency services immediately if the person is unresponsive, breathing abnormally, or showing blue discoloration
- 2. Place the person in the recovery position (on their side, head tilted back) to prevent choking if they vomit
- 3. Do not leave an unconscious or heavily sedated person alone
- 4. Do not induce vomiting
- 5. Monitor breathing continuously until help arrives
What to tell the dispatcher: Name the substance (pyrazolam, a designer benzodiazepine), the approximate amount taken, the time of ingestion, any other substances involved, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agent: Flumazenil is a benzodiazepine antagonist available in hospital settings. It can reverse benzodiazepine effects but carries risk of precipitating seizures in dependent individuals and has a shorter duration of action than pyrazolam — re-sedation can occur after the flumazenil wears off.[16]
Legal Status[edit]
Pyrazolam's legal status varies widely by country, reflecting the broader regulatory lag that has characterized responses to designer benzodiazepines as a class.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Not specifically scheduled | Not listed under the Controlled Substances Act as of May 2026. Five other designer benzodiazepines (etizolam, clonazolam, diclazepam, flualprazolam, flubromazolam) have been placed in temporary Schedule I. The Federal Analogue Act may apply if pyrazolam is intended for human consumption.citation needed |
| United States (Alabama) | Schedule I | Controlled since March 18, 2014 — one of the earliest state-level scheduling actions for any designer benzodiazepine.citation needed |
| United Kingdom | Class C, Schedule 2 (Misuse of Drugs Act 1971) | Scheduled via the Misuse of Drugs Act 1971 (Amendment) Order 2017, effective June 2017. Classified alongside diclazepam, flubromazepam, and etizolam.[5] |
| Germany | Controlled (NpSG) | Placed under the Neue-psychoaktive-Stoffe-Gesetz since July 18, 2019. Not scheduled under the BtMG (Narcotics Act).citation needed |
| Sweden | Controlled substance | Specifically scheduled. Pyrazolam has been identified in Swedish STRIDA project intoxication cases.[17] |
| Canada | Ambiguous | Not explicitly named in Schedule IV of the Controlled Drugs and Substances Act. Health Canada's position is that the benzodiazepine class definition may capture unnamed analogs, but pyrazolam's precise status has not been adjudicated.safety citation needed |
| Australia | Controlled substance (ODC listing) | Listed by the Office of Drug Control. Specific schedule number and effective date not confirmed.safety citation needed |
Pyrazolam was first reported to the EMCDDA Early Warning System in 2013.[10]
Legal status changes frequently and varies by jurisdiction. The information above reflects the best available data as of 2026 and is not legal advice. Verify current local law before acting on this information.
references
- [1] ^abNot specified in web search results (2026) In vitro γ-aminobutyric acid A (GABAA) receptor activity and binding interactions at the α+/γ2– interface of 53 prescription and designer benzodiazepines — Communications Chemistry (Nature) doi:10.1038/s42004-026-02001-x
- [2]
- [3] ^abMoosmann B, Huppertz LM, Hutter M, Buchwald A, Ferlaino S, Auwärter V (2013) Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics — Journal of Mass Spectrometry doi:10.1002/jms.3279
- [4]
- [5] ^abcdefghAbouchedid R, Gilks T, Dargan PI, Archer JRH, Wood DM (2018) Assessment of the Availability, Cost, and Motivations for Use over Time of the New Psychoactive Substances-Benzodiazepines Diclazepam, Flubromazepam, and Pyrazolam-in the UK — Journal of Medical Toxicology doi:10.1007/s13181-018-0659-3
- [6] ^abcdManchester KR, Lomas EC, Waters L, Dempsey FC, Maskell PD (2018) The emergence of new psychoactive substance (NPS) benzodiazepines: A review. — Drug testing and analysis doi:10.1002/dta.2211